Phase
Condition
Vascular Diseases
Scleroderma
Treatment
Placebo
Sildenafil
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hgwith a pulmonary capillary wedge pressure (or left ventricular end-diastolicpressure) ≤ 15 mm Hg within six months before study entry.
Diagnosis of SSc according to 2013 American College of Rheumatology/ European LeagueAgainst Rheumatism (ACR/EULAR) classification criteria.
Pulmonary function tests with forced expiratory volume in one second/forced vitalcapacity (FEV1/FVC) >50% AND either a) total lung capacity (TLC) or forced vitalcapacity (FVC) > 70% predicted or b) TLC or FVC between 60% and 70% predicted withno more than mild interstitial lung disease on computerized tomography scan of thechest on studies obtained within 6 months of enrollment.
Ventilation perfusion scan or computed tomography with intravenous contrast (CTangiogram) without evidence of chronic thromboembolism at anytime before studyentry.
Ability to perform six minute walk testing without significant limitations inmusculoskeletal function or coordination.
Informed consent.
Exclusion
Exclusion Criteria:
World Health Organization (WHO) Class IV functional status.
Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment.
Clinically significant untreated sleep apnea.
Left-sided valvular disease (more than moderate mitral valve stenosis orinsufficiency or aortic stenosis or insufficiency), pulmonary artery or valvestenosis, or ejection fraction < 45% on most recent echocardiography (within 1year).
Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues,endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat,selexipag) within the past 3 months.
Hospitalized or acutely ill.
Renal failure (creatinine above 2.0) at screening visit.
Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit.
Age < 18.
Currently pregnant.
Current use of nitrates.
Study Design
Study Description
Connect with a study center
Louisiana State University
New Orleans, Louisiana 70806
United StatesSite Not Available
Louisiana State University
New Orleans 4335045, Louisiana 4331987 70806
United StatesSite Not Available
Johns Hopkins
Baltimore, Maryland 21287
United StatesSite Not Available
Johns Hopkins
Baltimore 4347778, Maryland 4361885 21287
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.